| Literature DB >> 26274823 |
Miroslaw Janczura1, Grazyna Bochenek2, Roman Nowobilski3, Jerzy Dropinski2, Katarzyna Kotula-Horowitz2, Bartosz Laskowicz4, Andrzej Stanisz5, Jacek Lelakowski6, Teresa Domagala2.
Abstract
BACKGROUND AND AIMS: Higher levels of stress impact the prevalence of metabolic syndrome (MetS) and coronary heart disease. The association between MetS, impaired pulmonary function and low level of physical activity is still pending assessment in the subjects exposed to stress. The study aimed to examine whether higher levels of stress might be related to MetS and the plaque presence, as well as whether MetS might affect pulmonary function. DESIGN AND METHODS: The study embraced 235 police officers (mean age 40.97 years) from the south of Poland. The anthropometrics and biochemical variables were measured; MetS was diagnosed using the International Diabetes Federation criteria. Computed tomography coronary angiography of coronary arteries, exercise ECG, measurements of brachial flow-mediated dilation, and carotid artery intima-media thickness were completed. In order to measure the self-perception of stress, 10-item Perceived Stress Scale (PSS-10) was applied. Pulmonary function and physical activity levels were also addressed. Multivariate logistic regression analyses were applied to determine the relationships between: 1/ incidence of coronary plaque and MetS per se, MetS components and the number of classical cardiovascular risk factors, 2/ perceived stress and MetS, 3/ MetS and pulmonary function parameters.Entities:
Mesh:
Year: 2015 PMID: 26274823 PMCID: PMC4537246 DOI: 10.1371/journal.pone.0133750
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of the study subjects.
| Study variable | Value |
|---|---|
| N (F) | 235 (19) |
| Age, years | 40.97 (6.26) |
| Framingham Risk Score | 5.82 (5.11) |
| W/H ratio | 0.94 (0.06) |
| Overweight, n (%) | 101 (42.97) |
| Obesity, n (%) | 103 (43.83) |
| Dyslipidemia, n (%) | 120 (51.06) |
| Diabetes mellitus, n (%) | 7 (2.97) |
| Hypertension, n (%) | 104 (44.25) |
| Stable CHD, n (%) | 17 (7.23) |
| Positive family history of CHD, n (%) | 128 (54.46) |
| History of myocardial infarction, n (%) | 1 (0.42) |
| PCI, n (%) | 5 (2.13) |
| Smoking status, n (%) Never Current Past Pack-years | 96 (40.85)79 (33.62)60 (25.53)17.68 (11.83) |
| COPD, n (%) | 0 |
| Treatments, n (%) Aspirin ACEI/ARB β-blocker Ca-blocker Diuretics Lipid-lowering drugs Anti diabetic drugs | 8 (3.40)44 (18.72)42 (17.87)14 (5.97)30 (12.76)13 (5.53)7 (2.97) |
* Data are expressed as mean (SD); Framingham Risk Score, 10-year risk of developing coronary heart disease; W/H ratio, waist/hip; CHD, coronary heart disease; PCI, percutaneous coronary intervention; BMI, body mass index; ACEI, Angiotensin converting enzyme inhibitors; ARB, Angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease. Obesity was defined as BMI>30.0 kg/m2 and overweight as BMI >25.0 kg/m2.
Characteristics of the study subjects stratified by metabolic syndrome status.
| Study variable | Metabolic Syndrome | Non-Metabolic Syndrome | p value |
|---|---|---|---|
| N (F) | 109 (4) | 126 (15) | 0.038 |
| Age, years | 42.54 (6.75) | 39.61 (5.48) | <0.001 |
| Framingham Risk Score | 8.32 (5.26) | 3.43 (2.99) | <0.0001 |
| BMI, kg/m2 | 32.27 (3.73) | 27.78 (3.28) | <0.0001 |
| W/H ratio | 0.98 (0.04) | 0.91(0.06) | <0.0001 |
| Systolic blood pressure, mm Hg | 137.93 (16.93) | 124.15 (15.53) | <0.0001 |
| Diastolic blood pressure, mm Hg | 87.66 (10.48) | 80.36 (9.79) | <0.0001 |
| Stable CHD, n (%) | 12 (11.01) | 5 (3.96) | 0.053 |
| Positive result of stress ECG; n (%) | 18 (18.37) | 7 (6.60) | 0.012 |
| Coronary plaque burden, n (%) | 29 (37.66) | 14 (18.18) | 0.007 |
| FMD, % | 7.80 (3.23) | 8.17 (3.71) | 0.59 |
| IMT, mm | 0.59 (0.10) | 0.54 (0.09) | 0.0002 |
| Smoking status, n (%) | |||
| Never Current Past | 35 (32.11)40 (36.69)34 (31.19) | 61 (48.41)39 (30.95)26 (20.63) | 0.010.350.06 |
| Total cholesterol, mmol/L | 5.61 (1.01) | 5.02 (0.88) | <0.0001 |
| LDL cholesterol, mmol/L | 3.25 (0.86) | 3.02 (0.76) | 0.056 |
| HDL cholesterol, mmol/L | 1.12 (0.25) | 1.37 (0.35) | <0.0001 |
| Triglycerides, mmol/L | 2.92 (1.76) | 1.35 (0.75) | <0.0001 |
| Glucose, mmol/L | 5.72 (1.29) | 5.08 (0.39) | <0.0001 |
| CRP, mg/L | 2.18 (2.35) | 1.55 (1.78) | 0.0001 |
| TNF-α, pg/mL | 1.70 (2.85) | 1.25 (2.04) | 0.06 |
Data are expressed as mean (SD); BMI, body mass index; W/H, waist/hip; CHD, coronary heart disease; FMD, flow-mediated dilation; IMT, intima-media thickness; LDL, low density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein; TNF-α, tissue necrotic factor-α;
* n (%) subjects who underwent stress ECG;
** n (%) subjects who underwent computed tomography coronary angiography.
Models of logistic regression analysis: assessment of the impact of metabolic syndrome on the coronary plaque prevalence, depending on the correcting variable.
| Regression Model | Estimate | 95% CI | Wald Chi-Square | P | OR | 95% CI |
|---|---|---|---|---|---|---|
| 0* | 0.053 | -0.024–0.131 | 1.87 | 0.17 | 1.05 | 0.97–1.14 |
| 1 | 0.96 | 0.21–1.70 | 6.51 | 0.01 | 2.62 | 1.24–5.52 |
| 2 | 0.76 | -0.02–1.56 | 3.64 | 0.0451 | 2.16 | 1.02–4.78 |
| 3 | 0.73 | 0.25–1.36 | 3.53 | 0.0494 | 2.09 | 1.02–4.76 |
| 4 | 0.94 | 0.05–1.83 | 4.38 | 0.030 | 2.56 | 1.05–6.26 |
| 5 | 0.71 | -0.21–1.64 | 2.34 | 0.0498 | 2.04 | 1.01–5.17 |
Data are expressed as ORs and corresponding 95% CIs.
OR, odd ratio; CI, confidence interval;
Model 0*—perceived stress score, unadjusted;
Model 1 –metabolic syndrome, unadjusted,
Models 2–5, metabolic syndrome adjusted for: 2—age; 3—age, sex and smoking;
4—sex, smoking and perceived stress score; 5—age, sex, smoking and perceived stress score.
Results of logistic regression analysis: odds ratios for coronary plaque prevalence according to MetS components adjusted for age, sex, smoking and perceived stress score.
| Variable | Estimate | 95% CI | Wald Chi-Square | P | OR | 95% CI |
|---|---|---|---|---|---|---|
| WaistCircumference | 0.035 | -0.010–0.081 | 2.303 | 0.129 | 1.035 | 0.98–1.08 |
| Hypertension | 0.047 | 0.011–0.083 | 6.650 | 0.009 | 1.048 | 1.011–1.087 |
| Hypertriglycerydemia | 0.047 | -0.353–0.448 | 0.055 | 0.814 | 1.048 | 0.702–1.565 |
| Low HDL cholesterol | 0.103 | -0.252–0.458 | 0.327 | 0.567 | 1.108 | 0.776–1.581 |
| Elevated FBG | 0.160 | -0.217–0.539 | 0.706 | 0.40 | 1.17 | 0.804–1.715 |
| Age | 0.103 | 0.027–0.180 | 7.321 | 0.006 | 1.109 | 1.028–1.197 |
| Sex | 0.912 | -0.783–2.608 | 1.132 | 0.287 | 2.491 | 0.456–13.583 |
| Smoking | 0.468 | -0.403–1.339 | 1.129 | 0.287 | 1.597 | 0.668–3.817 |
| PSS | 0.051 | 0.001–0.098 | 4.149 | 0.041 | 1.051 | 1.001–1.103 |
Data are expressed as ORs and corresponding 95% CIs.
OR, odd ratio; CI, confidence interval; PSS, perceived stress score.
* ≥ 94/80 cm (men/women). Hypertension was defined as blood pressure systolic/diastolic ≥130/≥85 mm Hg or treatment of previously diagnosed hypertension; hypertriglyceridemia was defined as total triglycerides ≥1.7 mmol/L (150.0 mg/dL) or specific treatment for this lipid abnormality, low HDL-cholesterol was defined when cholesterol in this lipoprotein fraction was <1.03 mmol/L (40.0 mg/dL) in men and <1.29 mmol/L (50.0 mg/dL) in women; elevated fasting blood glucose (FBG) was defined when fasting glucose ≥5.6 mmol/L (100.0 mg/dL) or previously diagnosed type 2 diabetes.
Results of logistic regression analysis: odds ratios of plaque prevalence according to CVD risk factors.
| Number of CVD risk factors | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| 3 | 7.15 | 1.47–34.76 | 0.01 | 5.67 | 1.07–29.85 | 0.03 |
| 4 | 8.83 | 1.83–42.56 | 0.006 | 6.85 | 1.34–34.93 | 0.01 |
| 5 | 10.60 | 1.99–56.25 | 0.005 | 6.50 | 1.060–39.90 | 0.04 |
| 6 | 11.00 | 1.60–75.25 | 0.013 | 9.05 | 1.24–66.23 | 0.02 |
Data are expressed as ORs and corresponding 95% CIs,
OR, odd ratio; CI, confidence interval; CVD, cardiovascular disease;
Reference point for CVD risk factors is 0–2.
Model 1- Adjusted for age and sex;
model 2—Adjusted for age, sex and perceived stress score.
Spirometry test results and the intensity of physical activity in the study subjects stratified by metabolic syndrome status.
| Study variable | Metabolic Syndromen = 109 (F; 4) | Non-Metabolic Syndrome n = 126 (F; 15) | p value |
|---|---|---|---|
| Spirometry test | |||
| FEV1 | 99.77 (10.36) | 103.55 (14.79) | 0.01 |
| VC | 100.54 (9.34) | 105.31 (14.45) | 0.0002 |
| FVC | 101.55 (9.73) | 106.42 (14.06) | 0.0004 |
| FEV1%VC | 81.04 (7.70) | 80.99 (9.18) | 0.65 |
| FEV1%FVC | 80.36 (6.06) | 80.97 (8.07) | 0.73 |
| FEF25 | 99.42 (19.49) | 102.64 (18.61) | 0.31 |
| FEF50 | 89.73 (25.09) | 89.17 (22.23) | 0.98 |
| FEF75 | 61.87 (22.30) | 65.85 (24.41) | 0.41 |
| ERV | 56.03 (33.34) | 78.48 (47.57) | 0.001 |
| Physical activity (Corrected MET-minutes/week/kg of body weight) | |||
| Work-related | 69.61 (69.18) | 73.64 (74.68) | 0.65 |
| Transport-related | 32.37 (38.96) | 44.38 (52.16) | 0.08 |
| Domestic and gardening activities | 48.02 (52.47) | 44.91 (57.00) | 0.48 |
| Leisure time | 18.32 (25.84) | 29.67 (27.15) | 0.0001 |
| Total walking | 58.45 (57.34) | 77.82 (73.88) | 0.08 |
| Total moderate | 58.11 (62.49) | 65.03 (69.65) | 0.33 |
| Total vigorous | 52.99 (55.33) | 52.01 (59.01) | 0.68 |
| Total physical activity | 168.32 (117.62) | 192.60 (151.84) | 0.22 |
Data (percent predicted) are expressed as mean (SD); FEV1, forced expiratory volume in 1 second; VC, Vital Capacity; FVC, forced vital capacity; FEV1%VC, Tiffenau index; FEV1/FVC, a ratio of forced expiratory volume in 1 second (FEV1) to a forced vital capacity (FVC); FEF, forced expiratory flow; ERV, expiratory reserve volume; MET, Metabolic Equivalent of Task.